A second Duchenne muscular dystrophy patient died after being treated with the gene therapy delandistrogene moxeparvovec (Elevidys), Sarepta Therapeutics said Sunday.

Shares of Sarepta Therapeutics plunged Monday after the biotech drugmaker reported a second death in connection with its gene therapy for muscular dystrophy.

Pentacam and corneal topography were more sensitive to tear film abnormalities when measuring the curvature of the cornea in those with dry eye.

A corneal ulcer is an open sore or wound on the cornea — the transparent, dome-shaped surface that covers the front of the eye and focuses light into it. Often beginning as keratitis ...

Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy ...

Design Therapeutics will present DT-168 program updates for Fuchs endothelial corneal dystrophy at Eyecelerator on May 2, 2025.

Sight-robbing injuries to the cornea can be repaired using a groundbreaking experimental stem cell treatment, a new study shows. The cornea -- the clear outermost layer of the eye -- can become ...

A new therapy repairs corneal damage to a patient's eye using stem cells from their other, healthy eye.

Edgewise Therapeutics’ lead candidate has been shown to reduce levels of a biomarker related to skeletal muscle damage in a phase 2 trial.

Fuchs’ Corneal Dystrophy Causes and Risk Factors The innermost layer of your cornea, called the endothelium, removes fluids from the cornea to keep it clear.

Corneal dystrophies are a group of rare diseases that cause build-up of foreign matter in the layers of the cornea. Some lead to vision loss. Learn more.

Fuchs' dystrophy is an inherited condition affecting the cornea that can cause impaired vision and discomfort, but treatments are available.